The Herlev Hospital Post Radiation Therapy for Localized Prostate Cancer Database for Sexual Side Effects

The aim of this study is:

* To investigate which sexual side effects occur after external beam radiation therapy and brachie therapy
* To investigate how many patients are affected
* To investigate if there is a time dependency for the severity of the sexual side effects
* To investigate if there is a dose dependency for the severity of the sexual side effects
* To find predicting and associated factors for the discovered sexual side effects to help identifying patients at risk

Aim:

According to the European Association of Urology guidelines radical prostatectomy (RP) and external beam radiation therapy (EBRT) are considered equal treatments with curative intends, for localized prostate cancer \[1\]. Another type of radiation therapy used to treat localized prostate cancer is brachytherapy (BT). After both RP and EBRT some patients suffer a degree of erectile dysfunction (ED) and urinary incontinence (UI) \[2-5\]. However, current evidence shows that rates are lower with EBRT \[4,5\]. Unfortunately, EBRT hold the potential for late-onset toxicity and can, in a small percentage of the patients, lead to secondary genitourinary or gastrointestinal cancers \[5\]. In a recent study of RP patients at Herlev hospital, the investigators found that many patients, in addition to ED and UI, also suffered from UI during sexual activity, Orgasmic dysfunction, and penile morphological and sensory changes \[6\]. Only few studies have investigated these side effects in EBRT and BT patients.

The aim for this study is therefore:

* To investigate which sexual side effects occur after EBRT and BT
* To investigate how many patients are affected
* To investigate if there is a time dependency for the severity of the sexual side effects
* To investigate if there is a dose dependency for the severity of the sexual side effects
* To find predicting and associated factors for the discovered sexual side effects to help identifying patients at risk

Background:

As mentioned above, very few studies have investigated sexual side effects aside from ED in EBRT patients. O'Neil et al found that out of 110 EBRT patients 5.2% reported to have orgasm associated UI; while, 28.3% of the 279 RP patients queried reported the problem \[7\]. Penile shortening have has consistently been found after RP \[8\]. However, after both brachytherapy and ERBT in conjunction with androgen deprivation therapy penile shortening have has also been described \[9\] . Sullivan et al. investigated ejaculatory profiles en men undergoing radiation therapy (RT), either EBRT, brachytherapy, or a combination of both \[10\]. They found that 5 years after RT 89% of the patients reported anejaculation. During the 5 years of follow up patients reported increasingly bad scores, as measured by the orgasm domain of the international index of erectile function (IIEF).

Research plan, participants, and methods:

Because of the apparent shortage of studies with the main aim of investigating sexual side effects other than ED after EBRT and BT, the investigators want conduct a single center cross-sectional questionnaire based study which will be comparable to our study on RP side effects \[6\]. The investigators hope to document how many patients are affected by UI during sexual stimulation, altered perception of orgasm, anejaculation, orgasm-associated pain, penile shortening, altered penile curvature, and penile sensory changes. Furthermore we want to identify predicting and associated factors to better understand why and when these side effects occur.

The study will start in September 2014 and the investigators anticipate to have completed data collection in December 2014. Initially the investigators plan to invite 20 patients to participate in interview sessions where they will be given the opportunity to contribute to the design of the questionnaire. When the final questionnaire is ready all suited patients will receive the questionnaire by mail. Initial non-responders will receive another questionnaire 4-6 weeks later in order to get as many answers as possible. In order to grant us permission to search the patients´ journals for background information all patients will receive an informed consent formula to sign.

Recruiting of patient and informed consent:

Patients will be identified through hospital records. Initially 10 EBRT patients and 10 BT patients will be contacted by telephone in order to arrange the interview sessions. The remaining patients will only be contacted by mail as described above. Patients will be informed of the purpose of the study and that the final publication of study result will be kept anonymous. Patients will be asked to state that they accept the publication.

The initial questionnaires will be accompanied by a letter explaining the importance of participating. One month after the questionnaires are expected to have been received by the patients a reminder will be send to non-responders.

Publication of results:

The final results will be published in a peer reviewed international journal as soon as possible. Should that not be possible the results will be made public on our hospitals internet homepage. Prevalence rates will be the main outcomes; while Univariate and multivariate logistic regression analyses will be used for the purpose of identifying associated and predicting factors.

Ethics:

The study will be carried out according to the rules stated in the declaration of Helsinki and Danish law concerning health care research. The study is approved by the Danish data protection agency and registered at clinicaltrials.org.

Hopefully this study can help adding valuable knowledge to an area that is largely undiscovered. In addition, the investigators expect these results to help draw a clearer picture of the pros and cons of RP, BT, and EBRT as treatments for localized prostate cancer. Finally, this study should help patients suffering sexual side effects after EBRT by making practitioners aware of their existence and providing them with knowledge to better inform future patients.

Eligibility Criteria:
Inclusion Criteria:

* All patients must have received EBRT or BT with curative intent for localized prostate cancer.
* Only patients who have received EBRT or BT between 3 months and 5 years prior the start of the study will be enrolled.

Exclusion Criteria:

* Patients who had symptoms corresponding to the abovementioned side effects before EBRT